AGF Investments Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 251,762 shares of the company’s stock after selling 12,744 shares during the period. AGF Investments Inc.’s holdings in Johnson & Johnson were worth $30,528,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the stock. Americafirst Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at about $101,000. INR Advisory Services LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at about $150,000. Capital Asset Advisory Services LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at about $202,000. NewSquare Capital LLC raised its stake in shares of Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock valued at $217,000 after buying an additional 83 shares during the period. Finally, Shayne & CO. LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at about $219,000. Institutional investors own 65.32% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded down 0.3366% during mid-day trading on Tuesday, hitting $118.4101. 3,460,898 shares of the stock traded hands. Johnson & Johnson has a 52-week low of $92.58 and a 52-week high of $126.07. The firm has a market cap of $323.96 billion, a P/E ratio of 22.0667 and a beta of 0.62. The firm’s 50-day moving average is $119.10 and its 200 day moving average is $116.88.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.06. The firm earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. Equities analysts predict that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were given a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 2.69%. The ex-dividend date of this dividend was Friday, August 19th. Johnson & Johnson’s dividend payout ratio is presently 60.15%.
A number of research firms have weighed in on JNJ. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 28th. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 target price on the stock in a report on Monday, August 22nd. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a report on Thursday, August 25th. Finally, Deutsche Bank AG reissued a “buy” rating and set a $142.00 target price on shares of Johnson & Johnson in a report on Friday, August 19th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $120.19.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the transaction, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.